This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Advanz Pharma says UK competition court erred over ruling on thyroid drug pricing

By Simon Zekaria ( December 3, 2024, 16:33 GMT | Insight) -- Advanz Pharma told appeal judges today that the UK competition court handed down a flawed ruling when it supported the Competition and Markets Authority's infringement case against the company over the pricing of a thyroid drug. In a verdict from August last year, the Competition Appeal Tribunal dismissed Advanz' argument that that the price it charged health authorities for liothyronine sodium tablets wasn't excessive or unfair under antitrust rules.Advanz Pharma told appeal judges today that the UK competition court erred when it supported the Competition and Markets Authority's infringement case against the company over the pricing of a thyroid drug....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections